Expression and clinicopathological correlations of retinoid acid receptor responder protein 1 in renal cell carcinomas-Reference-Cited by-同舟云学术

Expression and clinicopathological correlations of retinoid acid receptor responder protein 1 in renal cell carcinomas

Published:2016-07 Issue:7 Volume:10 Page:721-732
ISSN:1752-0363
Container-title:Biomarkers in Medicine
language:en
Short-container-title:Biomarkers in Medicine

Author:

Zimpfer Annette¹²,Dammert Friedericke¹,Glass Aenne³,Zettl Heike⁴,Kilic Ergin⁵,Maruschke Matthias⁶⁷,Hakenberg Oliver W⁷,Erbersdobler Andreas¹

Affiliation:

1. Institute of Pathology, University Medicine Rostock, Strempelstr. 14, 18055 Rostock, Germany

2. Institute of Pathology, University Hospital of Jena, Ziegelmühlenweg 1, 07743 Jena, Germany

3. Institute of Biostatistics, University of Rostock, Ernst-Heydemann-Str. 8, 18057 Rostock, Germany

4. Clinical Cancer Registry, University Medicine Rostock, Südring 75, 18059 Rostock, Germany

5. Institute of Pathology, Charité University Medicine, Chariteplatz 1, 10177 Berlin Germany

6. Clinic of Urology, HELIOS Hanseklinikum Stralsund, Große Parower Straße 47–53, 18435 Stralsund, Germany

7. Clinic of Urology, University Medicine Rostock, Ernst-Heydemann-Str. 8, 18057 Rostock, Germany

Abstract

Aim: To evaluate the expression and prognostic value of RARRES1 at protein level in renal cell carcinoma (RCC). Materials & methods: Expression profile of RARRES1 was analyzed in 903 documented RCC followed by clinicopathological correlations and survival analysis. Results: RARRES1 expression was seen in 72.5% of RCC. A stronger RARRES1 expression was seen in high grade compared with low grade RCC (p < 0.001). Logrank tests revealed shorter overall survival in RARRES1 positive RCC (p = 0.006) and in pT1/2 tumors with RARRES1 expression (p = 0.002). Conclusion: The variable expression profile in low and high grade RCC may reflect and confirm the differences of previous gene expression analysis. There was a significant prognostic value of RARRES1 expression in patients with RCC, especially in pT1/2 tumors.

Publisher

Future Medicine Ltd

Subject

Biochemistry (medical),Clinical Biochemistry,Drug Discovery

Link

https://www.futuremedicine.com/doi/pdf/10.2217/bmm.16.12

Reference27 articles.

1. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

2. The Epidemiology of Renal Cell Carcinoma

3. Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s

4. Epidemiology of Renal Cell Carcinoma

5. Renal Tumors

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of tazarotene-induced gene 1 in carcinogenesis: is it a tumor suppressor gene or an oncogene?;BIOCELL;2024

2. Multi-omics analysis uncovers clinical, immunological, and pharmacogenomic implications of cuproptosis in clear cell renal cell carcinoma;European Journal of Medical Research;2023-07-22

3. Ceruloplasmin expression in renal cell carcinoma correlates with higher-grade and shortened survival;Biomarkers in Medicine;2021-08

4. Sexual dimorphism in cancer: insights from transcriptional signatures in kidney tissue and renal cell carcinoma;Human Molecular Genetics;2021-02-02

5. Cathepsin V Mediates the Tazarotene-induced Gene 1-induced Reduction in Invasion in Colorectal Cancer Cells;Cell Biochemistry and Biophysics;2020-09-12